[JPM 2025] Celltrion highlights breakthrough therapies, unveils ambitious clinical plans by 2028
SAN FRANCISCO -- Celltrion unveiled a detailed road map for its innovative drug pipeline to global investors and expressed commitment to becoming a leading global player in innovative pharmaceuticals, expanding forward from a biosimilar-focused company.
At the JP Morgan Healthcare Conference's main stage venue Tuesday, Celltrion CEO Seo Jin-seok delivered a presentation titled "Unveiling Strategy for Advancing Innovative Drug Pipelines," sharing its achievements in drug development and plans for future advancements.
"We successfully achieved our vision of building an 11-product portfolio last year, ahead of our original target of 2025, demonstrating our strong capabilities in developing antibody biopharmaceuticals," Seo said during the presentation. "Celltrion is leveraging its extensive experience to accelerate next-generation drug development, focusing on ADCs and multispecific antibody therapeutics, as key growth drivers."
Celltrion introduced its Biobetter ADCs, including CT-P70 for non-small cell lung cancer and CT-P71 for bladder cancer, which utilize a newly developed payload called PBX-7016. This payload, developed through open innovation, demonstrates low toxicity and high tumor growth inhibition, positioning it as a best-in-class platform for future therapies. The company also announced plans to develop Bispecific ADCs that target two molecules and Dual-Payload ADCs that combine payloads to maximize therapeutic effectiveness.
In addition to ADCs, Celltrion is focusing on multispecific antibodies, recognizing their potential to address unmet medical needs.
Key projects include CT-P72, a drug designed to selectively target cancer cells while minimizing toxicity, as well as conditionally- active multispecific antibodies that activate only in cancerous environments and immuno-oncology multispecific antibodies that enhance the antitumor effects of immune cells.
Seo outlined Celltrion’s clinical trial road map, detailing plans to submit 13 investigational new drug applications by 2028, including filings for CT-P70, CT-P71, CT-P73 and CT-P72 this year, followed by additional ADCs and multispecific antibodies in subsequent years.
"We began new drug development seven years ago and spent five years identifying the most suitable areas for Celltrion. We selected two modalities and achieved rapid progress in results within just two years," the CEO explained. "Celltrion has completed over 40 biosimilar clinical studies from start to finish, outperforming other biopharmaceutical companies. So I’m confident in our ability to maintain this pace and attract interest from investors in such a promising field."
Celltrion Group founder and Chair Seo Jung-jin took the stage for a Q&A session to engage directly with investors and share the company’s ambitious vision.
"Beyond expanding our ongoing biosimilar projects, Celltrion announced to newly enter the CDMO business," the chair said, referring to contract development and manufacturing. "I am eager to collaborate with and invest on rising entrepreneurs who have innovative ideas and research but may lack strategies and funding. I am pleased to partner with them and provide support through our strong CRO (contract researching) and CDMO services."
Copyright © 코리아헤럴드. 무단전재 및 재배포 금지.